Last €77.05 EUR
Change Today -0.08 / -0.10%
Volume 2.3M
SAN On Other Exchanges
EN Paris
EN Paris
New York
EN Paris
As of 11:35 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/13 - €87.03
52 Week Low
02/6/14 - €68.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI (SAN)

sanofi (SAN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi (SAN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi (SAN) Key Developments

Sanofi May Expand Production In Russia Through Acquisitions

Sanofi (ENXTPA:SAN) is looking at the possibility of expanding production in Russia, Sanofi's Vice president, Patrick Aghanian, said. Aghanian said Sanofi will consider setting up new production in one of Russia's regions, including Leningrad region, as well as the acquisition of existing Russian pharmaceutical companies. Aghanian did not say how much Sanofi is willing to spend on building a new plant or acquiring a new asset.

Sanofi In Talks To Sell Plasil

Sanofi (ENXTPA:SAN) is seeking to divest one of its traditional medicines Plasil (metoclopramide). Aspen Pharmacare Holdings Limited (JSE:APN), Farmoquímica S.A. and Laboratório Daudt Oliveira Ltda. are among those interested in acquiring Plasil. Negotiations for the divestment are expected to be completed in the next few days. Aspen Pharma is interested in purchasing the product in Brazil and Latin America.

Sanofi Launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis® starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €77.05 EUR -0.08

SAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €96.70 EUR -0.50
Gilead Sciences Inc $75.21 USD +2.35
GlaxoSmithKline PLC 1,643 GBp +2.50
Merck & Co Inc $57.42 USD -0.35
Novo Nordisk A/S kr243.30 DKK -1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SAN Industry Range
Price/Earnings 27.9x
Price/Sales 3.1x
Price/Book 1.8x
Price/Cash Flow 15.5x
TEV/Sales 2.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at